Imatinib mesylate for the treatment of canine mast cell tumors: assessment of the response and adverse events in comparison with the conventional therapy with vinblastine and prednisone (2022)
- Authors:
- USP affiliated authors: BRANDÃO, PAULO EDUARDO - FMVZ ; FUKUMASU, HEIDGE - FZEA ; MELO, SAMANTA RIOS - FMVZ ; DAGLI, MARIA LUCIA ZAIDAN - FMVZ ; PINTO, ANA CAROLINA BRANDÃO DE CAMPOS FONSECA - FMVZ ; MATERA, JULIA MARIA - FMVZ
- Unidades: FMVZ; FZEA
- DOI: 10.3390/cells11030571
- Subjects: CÃES; IMUNOHISTOQUÍMICA; MASTOCITOMA ANIMAL
- Keywords: imatinib mesylate; immunohistochemistry; mast cell tumor; prednisone; vinblastine
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
MACEDO, Thais Rodrigues et al. Imatinib mesylate for the treatment of canine mast cell tumors: assessment of the response and adverse events in comparison with the conventional therapy with vinblastine and prednisone. Cells, v. 11, n. 3, p. 1-12, 2022Tradução . . Disponível em: https://doi.org/10.3390/cells11030571. Acesso em: 13 fev. 2026. -
APA
Macedo, T. R., Queiroz, G. F. de, Casagrande, T. A. C., Alexandre, P. A., Brandão, P. E., Fukumasu, H., et al. (2022). Imatinib mesylate for the treatment of canine mast cell tumors: assessment of the response and adverse events in comparison with the conventional therapy with vinblastine and prednisone. Cells, 11( 3), 1-12. doi:10.3390/cells11030571 -
NLM
Macedo TR, Queiroz GF de, Casagrande TAC, Alexandre PA, Brandão PE, Fukumasu H, Melo SR, Dagli MLZ, Pinto ACB de CF, Matera JM. Imatinib mesylate for the treatment of canine mast cell tumors: assessment of the response and adverse events in comparison with the conventional therapy with vinblastine and prednisone [Internet]. Cells. 2022 ; 11( 3): 1-12.[citado 2026 fev. 13 ] Available from: https://doi.org/10.3390/cells11030571 -
Vancouver
Macedo TR, Queiroz GF de, Casagrande TAC, Alexandre PA, Brandão PE, Fukumasu H, Melo SR, Dagli MLZ, Pinto ACB de CF, Matera JM. Imatinib mesylate for the treatment of canine mast cell tumors: assessment of the response and adverse events in comparison with the conventional therapy with vinblastine and prednisone [Internet]. Cells. 2022 ; 11( 3): 1-12.[citado 2026 fev. 13 ] Available from: https://doi.org/10.3390/cells11030571 - Feline injection site sarcoma: immunohistochemical characteristics
- Characterization of patients with feline injection-site sarcoma as body condition score and as to the origin of its formation and their microenvironment
- Avaliação do prognóstico do mastocitoma canino através da expressão de KI-67 por imunoistoquímica
- Vascular endothelial growth factor expression and microvascular density in soft tissue sarcomas in dogs
- In vitro chemosensitivity of canine mast cell tumors grades II and III to all-trans-retinoic acid (ATRA)
- C-kit and C-kit ligand gene expression as prognostic factors for canine mast cell tumor
- Acupuntura e medicina herbal chinesa no tratamento de compressão extra-dural cervical: relato de caso em cão
- Análise cinética da locomoção de cães hígidos da raça Rottweiler
- Análise cinética da locomoção de cães da raça Bulldog Inglês
- Vertical forces assessment according to radiographic hip grade in German shepherd dogs
Informações sobre o DOI: 10.3390/cells11030571 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
BRA_281_3064628_R.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
